Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Protalix BioTherapeutics (PLX) over the last 13 years, with Q3 2025 value amounting to $1.5 million.

  • Protalix BioTherapeutics' Prepaid Assets rose 3828.57% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 3828.57%. This contributed to the annual value of $1.1 million for FY2024, which is 388.63% up from last year.
  • Per Protalix BioTherapeutics' latest filing, its Prepaid Assets stood at $1.5 million for Q3 2025, which was up 3828.57% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Prepaid Assets peaked at $3.0 million during Q2 2021, and registered a low of $758000.0 during Q1 2023.
  • In the last 5 years, Protalix BioTherapeutics' Prepaid Assets had a median value of $1.5 million in 2025 and averaged $1.5 million.
  • Per our database at Business Quant, Protalix BioTherapeutics' Prepaid Assets crashed by 3869.27% in 2021 and then skyrocketed by 9581.28% in 2025.
  • Protalix BioTherapeutics' Prepaid Assets (Quarter) stood at $1.3 million in 2021, then rose by 1.95% to $1.3 million in 2022, then fell by 19.47% to $1.1 million in 2023, then increased by 3.89% to $1.1 million in 2024, then skyrocketed by 32.48% to $1.5 million in 2025.
  • Its Prepaid Assets stands at $1.5 million for Q3 2025, versus $1.5 million for Q2 2025 and $1.6 million for Q1 2025.